OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

• DOI: 10.1016/j.jtho.2021.01.313
• Publication Date: 2021-03-20T05:57:17Z
• Authors: T. Owonikoko; M. Boyer; M. Johnson; R. Govindan; L. Rodrigues; F. Blackhall; R. Boosman; S. Champiat; H. Hummel; W.V. Lai; H. Udagawa; A. Chiang; A. Dowlati; C. Hann; R. Salgia; E. Vokes; M. Minocha; N. Sadraei; A. Shetty; M. Smit; Y. Zhang; B. Sable; A. Pati; S. Roy; H. Borghaei
• Keywords: 03 medical and health sciences; 0302 clinical medicine